Fig. 2

Mutational landscape of patients before and after NAC. A Co-mutation plot of oncogenic genetic variants in baseline tumors. B, C Bar plots showing the proportion of patients harboring specific mutations (B) and genetic variations categorized into ten oncogenic signaling pathways in baseline tumors (C). D, E Kaplan–Meier curves demonstrate the disease-free survival and overall survival of patients stratified by clinical stage (D) and baseline USH2A mutations (E)